Company Statement

Baxter has approximately 47,000 employees worldwide and conducts business in over 100 countries. In 2006 sales totalled $10.4 billion globally.

Baxter Healthcare has invested heavily in Australia and New Zealand. 

Australian operations commenced in 1963 and now comprise a manufacturing plant at Toongabbie; a sales and marketing facility joined with a technical service centre at Baulkham Hills; distribution and warehousing depots in NSW, QLD, VIC, SA, WA and TAS; aseptic compounding facilities in NSW, QLD, VIC and WA; and haemodialysis centres in QLD, VIC, WA and SA.

New Zealand operations commenced in 1980 and include a head office in Auckland; warehouse and distribution centres in Auckland and Christchurch; and an aseptic compounding pharmacies in Auckland and Waikato.

Baxter has approximately 47,000 employees worldwide and conducts business in over 100 countries. In 2006 sales totalled $10.4 billion globally.

Baxter Healthcare has invested heavily in Australia and New Zealand. 

Australian operations commenced in 1963 and now comprise a manufacturing plant at Toongabbie; a sales and marketing facility joined with a technical service centre at Baulkham Hills; distribution and warehousing depots in NSW, QLD, VIC, SA, WA and TAS; aseptic compounding facilities in NSW, QLD, VIC and WA; and haemodialysis centres in QLD, VIC, WA and SA.

New Zealand operations commenced in 1980 and include a head office in Auckland; warehouse and distribution centres in Auckland and Christchurch; and an aseptic compounding pharmacies in Auckland and Waikato.

Beginning more than 75 years ago, Baxter has been heavily involved in many medical breakthroughs we take for granted today: intravenous medicine, kidney dialysis, heart valve replacement, blood component therapy and haemophilia care.

Baxter 'firsts' include:

• The first manufactured IV solution
• The first blood storage system
• The first commercial artificial kidney
• The first needleless IV system
• The first clotting factor for hemophilia
• The first portable dialysis therapy

• The BioScience business unit is a leading manufacturer of plasma-based and recombinant proteins used to treat hemophilia, and other biopharmaceutical products, including plasma-based therapies to treat immune disorders, alpha-1 antitrypsin deficiency and other chronic blood-related conditions; biosurgery products for hemostasis, wound-sealing and tissue regeneration; and vaccines. The business also manufactures manual and automated blood and blood-component separation and collection systems.
  
• The Medication Delivery business unit is a leading manufacturer of intravenous (IV) solutions and administration sets, pre-mixed drugs and drug reconstitution systems, pre-filled vials and syringes for injectable drugs, electronic infusion pumps and other products used to deliver fluids and drugs to patients. The business also provides IV nutrition solutions, containers and compounding systems and services, general anaesthetic agents and critical care drugs, contract manufacturing services, and drug packaging and formulation technologies.
  
• The Renal business unit is a leading manufacturer of products for peritoneal dialysis (PD), a home therapy for people with end-stage renal disease, or irreversible kidney failure. These products include a range of PD solutions and related supplies to help patients safely perform fluid exchanges, as well as automated PD cyclers that perform solution exchanges for patients overnight while they sleep. The business also distributes products (hemodialysis instruments and disposables, including dialyzers) for hemodialysis, a form of dialysis generally conducted several times a week in a hospital or clinic.

Baxter is committed to ethical operations and so undertakes all business activities inline with leading industry regulatory bodies including: